AKESO INC. O.N. (4RY) - Total Assets
Based on the latest financial reports, AKESO INC. O.N. (4RY) holds total assets worth €16.00 Billion EUR (≈ $18.71 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
AKESO INC. O.N. - Total Assets Trend (2021–2025)
This chart illustrates how AKESO INC. O.N.'s total assets have evolved over time, based on quarterly financial data. Also see AKESO INC. O.N. stock valuation for the company's overall valuation and market capitalisation.
AKESO INC. O.N. - Asset Composition Analysis
Current Asset Composition (December 2025)
AKESO INC. O.N.'s total assets of €16.00 Billion consist of 70.5% current assets and 29.5% non-current assets. Review 4RY total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 54.9% |
| Accounts Receivable | €1.02 Billion | 6.4% |
| Inventory | €931.62 Million | 5.8% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €321.50 Million | 2.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how AKESO INC. O.N.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See AKESO INC. O.N. (4RY) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: AKESO INC. O.N.'s current assets represent 70.5% of total assets in 2025, an increase from 65.6% in 2021.
- Cash Position: Cash and equivalents constituted 54.9% of total assets in 2025, down from 55.0% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 3.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 6.4% of total assets.
AKESO INC. O.N. Competitors by Total Assets
Key competitors of AKESO INC. O.N. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
AKESO INC. O.N. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.14 | 5.15 | 4.79 |
| Quick Ratio | 4.71 | 4.73 | 4.43 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €9.08 Billion | €7.00 Billion | €5.34 Billion |
AKESO INC. O.N. - Advanced Valuation Insights
This section examines the relationship between AKESO INC. O.N.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.03 |
| Latest Market Cap to Assets Ratio | 0.65 |
| Asset Growth Rate (YoY) | 25.4% |
| Total Assets | €16.00 Billion |
| Market Capitalization | $10.42 Billion USD |
Valuation Analysis
Below Book Valuation: The market values AKESO INC. O.N.'s assets below their book value (0.65x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: AKESO INC. O.N.'s assets grew by 25.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for AKESO INC. O.N. (2021–2025)
The table below shows the annual total assets of AKESO INC. O.N. from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €16.00 Billion ≈ $18.71 Billion |
+25.44% |
| 2024-12-31 | €12.75 Billion ≈ $14.91 Billion |
+38.93% |
| 2023-12-31 | €9.18 Billion ≈ $10.73 Billion |
+67.05% |
| 2022-12-31 | €5.50 Billion ≈ $6.43 Billion |
+14.36% |
| 2021-12-31 | €4.81 Billion ≈ $5.62 Billion |
-- |
About AKESO INC. O.N.
Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, and liver cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell car… Read more